The present data support the use of LR-IL-22 in clinical protocols as a mitigator of radiotherapy in women suffering from advanced, recurrent, or cisplatin-resistant ovarian cancer with peritoneal disease dissemination who may benefit from WAI. This evidence concerns the gene IL22 and ovarian cancer.